Citations

Clear

431 citation(s) found for "Schmidt, C".

Natural History of Patients Diagnosed with Cardiac Sarcoidosis at Left Ventricular Assist Device Implantation or Cardiac Transplantation
Schmidt, Tyler , Rosenbaum, Andrew , Kolluri, Nikhil , Stulak, John M., Daly, Richard C. , Schirger, John A., Elwazir, Mohamed Y. , Kapa, Suraj , Blauwet, Lori A., Schmidt, Tyler J , Rosenbaum, Andrew N , Kapa, Suraj , Elwazir, Mohamed , Cooper, Leslie T.

Mayo Clinic

ASAIO Journal | September 6, 2020 | Volume: 67 | Issue: 5 | Pages: 583-587

10.1097/mat.0000000000001262 | PMID 33902104 Get It

To our knowledge, natural history has not been reported for cardiac sarcoidosis (CS) diagnosed by pathologic evaluation of the apical core at left ventricular assist device (LVAD) implantation or cardiac transplantation. We retrospectively identified 232 consecutive patients meeting CS criteria. Of these patients, 54 were diagnosed by pathologic confirmation of CS, 10 after evaluation of the apical core (LVAD implant) or explanted heart (transplant). We compared clinical characteristics at initial evaluation and outcomes for these 10 patients with those of 10 patients with known CS before LVAD implant/transplant. In the study group, five patients (50%) had confirmed extracardiac sarcoidosis before LVAD implant/transplant; five had not been diagnosed with sarcoidosis. Mean (standard deviation) left ventricular ejection fraction at initial evaluation was 23% (16%), and left ventricular end-diastolic dimension was 61 (10) mm. Four patients died during follow-up; however, no survival difference was found for the 10 patients diagnosed incidentally and the group with a previous diagnosis or institutional LVAD/transplant cohorts. Patients diagnosed with CS on pathological examination of the apical core/explanted heart may have severe dilated cardiomyopathy as the initial presentation. Outcomes for patients with CS after advanced heart failure therapies may be comparable with those of non-CS patients.
Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients
Finsterwalder, Sofia , Vlegels, Naomi , Caballero, Miguel Ángel Araque, Georgakis, Marios K. , (DIAN), Dominantly Inherited Alzheimer Network, Graff‐Radford, Neill R. , Salloway, Stephen , Oh, Hwamee , Chhatwal, Jasmeer P. , group, DELCODE study, Jessen, Frank , Düzel, Emrah , Dobisch, Laura, Metzger, Coraline D., Peters, Oliver , Incesoy, Enise I. , Priller, Josef , Spruth, Eike Jakob , Schneider, Anja , Fließbach, Klaus , Büerger, Katharina , Janowitz, Daniel , Kilimann, Ingo , Laske, Christoph , Buchmann, Martina, Heneka, Michael T. , Spottke, Annika , Roy, Nina, Ertl‐Wagner, Birgit , (ADNI), Alzheimer's Disease Neuroimaging Initiative, group, Utrecht VCI study, Seo, Sang Won , Na, Duk L. , Kim, Hee Jin, Ewers, Michael , Xiong, Chengjie , Schmidt, Reinhold , Pasternak, Ofer , Dichgans, Martin , Biessels, Geert Jan , Duering, Marco , Dichgans, Martin , Xiong, Chengjie , Gesierich, Benno G. , Weaver, Nick A. , Franzmeier, Nicolai , Konieczny, Marek J., Koek, Huiberdina L. , (DIAN), Dominantly Inherited Alzheimer Network, Karch, Celeste M. , Allegri, Ricardo , group, DELCODE study, Teipel, Stefan Johannes , Brosseron, Frederic , Scheffler, Klaus , (ADNI), Alzheimer's Disease Neuroimaging Initiative, group, Utrecht VCI study, Kim, Yeshin , Kim, Hee Jin, Jang, Hyemin , Biessels, Geert Jan , Duering, Marco

Mayo Clinic

Alzheimer's & Dementia | August 25, 2020 | Volume: 16 | Issue: 11 | Pages: 1504-1514

10.1002/alz.12150 | PMID 32808747 Get It

AbstractIntroductionMicrostructural alterations as assessed by diffusion tensor imaging (DTI) are key findings in both Alzheimer's disease (AD) and small vessel disease (SVD). We determined the contribution of each of these conditions to diffusion alterations.MethodsWe studied six samples (N = 365 participants) covering the spectrum of AD and SVD, including genetically defined samples. We calculated diffusion measures from DTI and free water imaging. Simple linear, multivariable random forest, and voxel‐based regressions were used to evaluate associations between AD biomarkers (amyloid beta, tau), SVD imaging markers, and diffusion measures.ResultsSVD markers were strongly associated with diffusion measures and showed a higher contribution than AD biomarkers in multivariable analysis across all memory clinic samples. Voxel‐wise analyses between tau and diffusion measures were not significant.DiscussionIn memory clinic patients, the effect of SVD on diffusion alterations largely exceeds the effect of AD, supporting the value of diffusion measures as markers of SVD.
Abstract A58: Curation of pediatric cancer variants within the Clinical Genome Resource (ClinGen)
Church, Alanna J. , Ritter, Deborah , Danos, Arpad , Krysiak, Kilann, Hiemenz, Matthew , Janeway, Katherine A. , Ji, Jianling , Laetsch, Theodore W. , Schmidt, Ryan J. , Sund, Kristen L. , Lin, Wan‐Hsin , Kulkarni, Shashikant , Madhavan, Subha , Roy, Angshumoy , Raca, Gordana , Rao, Shruti , Corson, Laura , Fisher, Kevin E. , Kesserwan, Chimene A. , Parsons, D. Williams , Griffith, Malachi , Griffith, Obi L.

Mayo Clinic

Cancer Research | August 12, 2020 | Volume: 80 | Issue: 14_Supplement | Pages: A58-A58

10.1158/1538-7445.pedca19-a58 Get It

Abstract Introduction: The Clinical Genome Resource (ClinGen) Somatic Working Group (sWG) is a multi-institution team engaged in developing processes, resources, and standards to support accurate classification of somatic variants in cancer. Existing decision support resources in cancer knowledgebases are heavily skewed towards genes and variants relevant in adult cancers; however, information to support variant interpretation in childhood cancers is limited. Here we report on the goals and progress of the Pediatric Cancer Taskforce, created within the ClinGen sWG, to lead curation efforts of actionable alterations in childhood cancers. Methods: The ClinGen sWG Pediatric Cancer Taskforce (PCT) consists of a core group of twelve members comprising geneticists, pathologists, and oncologists with expertise in different pediatric cancers and with representation from 9 leading pediatric institutions. The taskforce has a total of 35 members including volunteer-curators who work under guidance of the expert members. Curation of childhood cancer variants is conducted in collaboration with the Clinical Interpretation of Variants in Cancer (CIViC) team at Washington University in Saint Louis, using the CIViC knowledgebase (civicdb.org) and the ClinVar database as open-access curation and data-sharing platforms. Diagnostic, prognostic, and therapeutic evidence is tiered according to the AMP/ASCO/CAP guidelines for the clinical interpretation of somatic variants. PCT members are assigned specific genetic variant-tumor type associations for curation, which are then reviewed in monthly conferences to finalize assertions in CIViC. Results: The PCT has prioritized 40 genetic alterations relevant to pediatric cancer for curation based on their clinical relevance and the lack of sufficient existing curated evidence in clinical knowledgebases. To date, 4 assertions have been created and added to the database: HEY1-NCOA2 fusion in mesenchymal chondrosarcoma, KIAA1549-BRAF fusion and ACVR1 p.G328V variant in pediatric glioma, and EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia. Active curation has been initiated for NTRK fusions agnostic of tissue histology, targetable kinase fusions in Ph-like B-lymphoblastic leukemia, and common variants in selected pediatric sarcomas and brain tumors, focusing heavily on driver gene fusions in childhood cancers. 119 evidence items have been created in CIViC by the members. The PCT also works to implement more standardized and accurate classification of pediatric cancers in CIViC and other cancer resources, and to enhance search for pediatric-specific data through appropriate tagging of evidence using ontology terms. Conclusions: As molecular alterations are increasingly relevant to the care of children with cancer, the ClinGen PCT will work to develop standards, processes, and resources for efficient and accurate determination of clinical relevance of pediatric cancer variants. Citation Format: Alanna J. Church, Shruti Rao, Deborah Ritter, Arpad Danos, Kilann Krysiak, Laura B. Corson, Kevin E. Fisher, Matthew Hiemenz, Katherine A. Janeway, Jianling Ji, Chimene A. Kesserwan, Theodore W. Laetsch, Donald W. Parsons, Ryan J. Schmidt, Kristen L. Sund, Wan-Hsin Lin, Malachi Griffith, Obi L. Griffith, Shashikant Kulkarni, Subha Madhavan, Angshumoy Roy, Gordana Raca. Curation of pediatric cancer variants within the Clinical Genome Resource (ClinGen) [abstract]. In: Proceedings of the AACR Special Conference on the Advances in Pediatric Cancer Research; 2019 Sep 17-20; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Res 2020;80(14 Suppl):Abstract nr A58.
Imipenem-Relebactam Susceptibility Testing of Gram-Negative Bacilli by Agar Dilution, Disk Diffusion, and Gradient Strip Methods Compared with Broth Microdilution
Hakvoort, Hanna, Bovenkamp, Evelyn, Greenwood‐Quaintance, Kerryl E. , Schmidt-Malan, Suzannah M., Mandrekar, Jay , Patel, Robin , Mandrekar, Jay N., Patel, Robin , Schuetz, Audrey N.

Mayo Clinic

Journal of Clinical Microbiology | July 30, 2020 | Volume: 58 | Issue: 10 | Pages: No page available

10.1128/jcm.00695-20 | PMID 32727832 Get It

This study aimed to determine whether agar dilution, research-use-only disk diffusion (Mast Group Ltd., Bootle Merseyside, UK), Etest (bioMérieux, Inc., Durham, NC), and MIC test strip (MTS) (Liofilchem, Inc., Waltham, MA) methods yield equivalent results to those of broth microdilution (BMD) for imipenem-relebactam susceptibility testing using a collection of 297 Gram-negative bacilli, including members of the order Enterobacterales and Pseudomonas aeruginosa , enriched for drug resistance.
Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia
Scholand, Mary Beth , Lynch, David A. , Colby, Thomas V. , Groshong, Steve D. , Benzaquen, Sadia , Nathan, Steven D. , Davis, John R., Schmidt, Shelley L., Hagmeyer, Lars , Sonetti, David A., Hetzel, Jürgen, Case, Amy Hajari , Ramaswamy, Murali, Calero, Karel , Gauhar, Umair, Lancaster, Lisa , Choi, Yoonha, Pankratz, Daniel G., Walsh, P. Sean, Lofaro, Lori , Huang, Jing , Bhorade, Sangeeta , Kennedy, Giulia C., Raghu, Ganesh , Richeldi, Luca , Myers, Jeffrey L. , Chung, Jonathan Hero , Davis, J. Russell, Criner, Gerard J. , Patel, Nina , Martínez, Fernando J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 28, 2020 | Volume: 203 | Issue: 2 | Pages: 211-220

10.1164/rccm.202003-0877oc | PMID 32721166 Get It

Abstract Rationale Usual interstitial pneumonia (UIP) is the defining morphology of idiopathic pulmonary fibrosis (IPF). Guidelines for IPF diagnosis conditionally recommend surgical lung biopsy for histopathology diagnosis of UIP when radiology and clinical context are not definitive. A “molecular diagnosis of UIP” in transbronchial lung biopsy, the Envisia Genomic Classifier, accurately predicted histopathologic UIP. Objectives We evaluated the combined accuracy of the Envisia Genomic Classifier and local radiology in the detection of UIP pattern. Methods Ninety-six patients who had diagnostic lung pathology as well as a transbronchial lung biopsy for molecular testing with Envisia Genomic Classifier were included in this analysis. The classifier results were scored against reference pathology. UIP identified on high-resolution computed tomography (HRCT) as documented by features in local radiologists’ reports was compared with histopathology. Measurements and Main Results In 96 patients, the Envisia Classifier achieved a specificity of 92.1% (confidence interval [CI],78.6–98.3%) and a sensitivity of 60.3% (CI, 46.6–73.0%) for histology-proven UIP pattern. Local radiologists identified UIP in 18 of 53 patients with UIP histopathology, with a sensitivity of 34.0% (CI, 21.5–48.3%) and a specificity of 96.9% (CI, 83.8–100%). In conjunction with HRCT patterns of UIP, the Envisia Classifier results identified 24 additional patients with UIP (sensitivity 79.2%; specificity 90.6%). Conclusions In 96 patients with suspected interstitial lung disease, the Envisia Genomic Classifier identified UIP regardless of HRCT pattern. These results suggest that recognition of a UIP pattern by the Envisia Genomic Classifier combined with HRCT and clinical factors in a multidisciplinary discussion may assist clinicians in making an interstitial lung disease (especially IPF) diagnosis without the need for a surgical lung biopsy.
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
Rivera, Donna R. , Peters, Solange , Shah, Dimpy P. , Kuderer, Nicole M. , Hsu, Chih–Yuan , Rubinstein, Samuel M. , Lee, Brendan J., Choueiri, Toni K. , Lopes, Gilberto , Grivas, Petros , Arcobello, Jonathan , Bakouny, Ziad , Doroshow, Deborah B. , Egan, Pamela , Fecher, Leslie A. , Friese, Christopher R. , Galsky, Matthew D. , Gupta, Shilpa , Hálfdánarson, Þorvarður R. , Halmos, Balázs , Khaki, Ali Raza , Lemmon, Christopher A. , Mishra, Sanjay , Puc, Matthew , Revankar, Sanjay G. , Schapira, Lidia , Schmidt, Andrew , Shah, Sumit , Wu, Julie , Xie, Zhuoer , Yeh, Albert C. , Zhu, Huili , Shyr, Yu , Grivas, Petros , Bakouny, Ziad , Galsky, Matthew D , Goel, Sanjay , Halfdanarson, Thorvardur R , Hawley, Jessica E , Mishra, Sanjay , Pennell, Nathan A , Puc, Matthew M , Revankar, Sanjay G , Wu, Julie T , Yeh, Albert C , Warner, Jeremy L , Peters, Solange , Choueiri, Toni K , Xie, Zhuoer , Khaki, Ali Raza , Panagiotou, Orestis A. , Painter, Corrie , Rini, Brian I. , Thompson, Michael A. , Farmakiotis, Dimitrios , Goel, Sanjay , Hawley, Jessica E. , Olszewski, Adam J. , Schwartz, Gary K. , Lyman, Gary H , Warner, Jeremy L. , Halmos, Balazs

Mayo Clinic

Cancer Discovery | July 22, 2020 | Volume: 10 | Issue: 10 | Pages: 1514-1527

10.1158/2159-8290.cd-20-0941 | PMID 32699031 Get It

Abstract Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19 treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as white patients. Although observational studies can be limited by potential unmeasured confounding, our findings add to the emerging understanding of patterns of care for patients with cancer and COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled trials. Significance: Evaluating the potential role of COVID-19 treatments in patients with cancer in a large observational study, there was no statistically significant 30-day all-cause mortality benefit with hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential benefit. Treatment receipt reflects clinical decision-making and suggests disparities in medication access. This article is highlighted in the In This Issue feature, p. 1426
Novel Use of Rifabutin and Rifapentine to Treat Methicillin-Resistant Staphylococcus aureus in a Rat Model of Foreign Body Osteomyelitis
Karau, Melissa J. , Schmidt-Malan, Suzannah M., Albano, Mariana , Mandrekar, Jayawant N. , Rivera, Christina G. , Osmon, Douglas R. , Oravec, Caitlin P., Berry, Daniel J. , Patel, Robin , Patel, Robin , Berry, Daniel J , Rivera, Christina G , Abdel, Matthew P.

Mayo Clinic

The Journal of Infectious Diseases | July 5, 2020 | Volume: 222 | Issue: 9 | Pages: 1498-1504

10.1093/infdis/jiaa401 | PMID 32914837 Get It

Abstract Background Owing to patient intolerance or drug interactions, alternative agents to rifampin are needed for management of staphylococcal periprosthetic joint infection. In the current study, we evaluated rifabutin, rifapentine and rifampin, with and without vancomycin, in a rat model of foreign body osteomyelitis. Methods Proximal tibiae were inoculated with methicillin-resistant Staphylococcus aureus (MRSA) and a Kirschner wire (K-wire) implanted in each. After 4 weeks of infection, rifampin, rifabutin, or rifapentine were administered, alone or with vancomycin. Tibiae and K-wires were cultured, and medians were reported as log10 colony-forming units (CFUs) per gram of bone or log10 CFUs per K-wire, respectively. Results Rifampin, rifabutin or rifapentine administered with vancomycin yielded less MRSA from bones (0.10, 3.02, and 0.10 log10 CFUs/g, respectively) than did no treatment (4.36 log10 CFUs/g) or vancomycin alone (4.64 log10 CFUs/g) (both P ≤ .02). The K-wires of animals receiving no treatment or vancomycin monotherapy recovered medians of 1.76 and 2.91 log10 CFUs/g per K-wire, respectively. In contrast, rifampin, rifabutin and rifapentine administered with vancomycin yielded medians of 0.1 log10 CFUs per K-wire, respectively. Rifampin resistance was detected in a single animal in the rifampin monotherapy group. Conclusions Rifabutin or rifapentine with vancomycin were as active as rifampin with vancomycin against MRSA in rat foreign body osteomyelitis, suggesting that rifabutin and/or rifapentine may be alternatives to rifampin in the clinical management of staphylococcal periprosthetic joint infections.
What is the Real Rate of Radial Nerve Injury After Humeral Nonunion Surgery?
Koh, Justin , Walker, Brock, Jones, Clifford B. , Sharmaa, Tayseer, Sems, S.A. , Ringenbach, Kathleen L., Boateng, Henry A. , Bellevue, Kate D., Saxena, Sharul, Cannada, Lisa K. , Borade, Amrut , Horwitz, Daniel S. , Buck, J. Stewart , Bosse, Michael J. , Westberg, Jerald R., Kempton, Laurence B. , Newcomb, Emily, Marcantonio, Andrew , Delarosa, Matthew, Gudeman, Andrew , Alhoukail, Amro, Leighton, Ross , Cortez, Abigail , Tieszer, Christina, Sanders, David , Patel, Shaan , Walker, J. Brock , Sems, Stephen, Tornetta, Paul , Walker, Brock, Firoozabadi, Reza , Spitler, Clay A. , Schmidt, Andrew H. , Krause, Peter C. , Mullis, Brian , Morshed, Saam , Mir, Hassan Riaz

Mayo Clinic

Journal of Orthopaedic Trauma | June 20, 2020 | Volume: 34 | Issue: 8 | Pages: 441-446

10.1097/bot.0000000000001755 | PMID 32569074 Get It

Objectives:To determine the radial nerve palsy (RNP) rate and predictors of injury after humeral nonunion repair in a large multicenter sample.Design:Consecutive retrospective cohort review.Setting:Eighteen academic orthopedic trauma centers.Patients/Participants:Three hundred seventy-nine adult patients who underwent humeral shaft nonunion repair. Exclusion criteria were pathologic fracture and complete motor RNP before nonunion surgery.Intervention:Humeral shaft nonunion repair and assessment of postoperative radial nerve function.Main Outcome:Measurements: Demographics, nonunion characteristics, preoperative and postoperative radial nerve function and recovery.Results:Twenty-six (6.9%) of 379 patients (151 M, 228 F, ages 18–93 years) had worse radial nerve function after nonunion repair. This did not differ by surgical approach. Only location in the middle third of the humerus correlated with RNP (P= 0.02). A total of 15.8% of patients with iatrogenic nerve injury followed for a minimum of 12 months did not resolve. For those who recovered, resolution averaged 5.4 months. On average, partial/complete palsies resolved at 2.6 and 6.5 months, respectively. Sixty-one percent (20/33) of patients who presented with nerve injury before their nonunion surgery resolved.Conclusion:In a large series of patients treated operatively for humeral shaft nonunion, the RNP rate was 6.9%. Among patients with postoperative iatrogenic RNP, the rate of persistent RNP was 15.8%. This finding is more generalizable than previous reports. Midshaft fractures were associated with palsy, while surgical approach was not.Level of Evidence:Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
Severe Capecitabine Toxicity Associated With a Rare DPYD Variant Identified Through Whole-Genome Sequencing
Ly, Reynold C. , Schmidt, Remington E. , Kiel, Patrick J. , Pratt, Victoria M. , Schneider, Bryan P. , Radovich, Milan , Diasio, Robert B. , Skaar, Todd C. , Offer, Steven M.

Mayo Clinic

JCO Precision Oncology | June 12, 2020 | Volume: No volume available | Issue: 4 | Pages: 632-638

10.1200/po.20.00067 | PMID 32923881 Get It

Common Genetic Variation Indicates Separate Causes for Periventricular and Deep White Matter Hyperintensities
Armstrong, Nicola J. , Mather, Karen A. , Sargurupremraj, Muralidharan , Knol, Maria J. , Malik, Rainer, Satizábal, Claudia L. , Yanek, Lisa R., Wen, Wei , Guðnason, Vilmundur , Dueker, Nicole , Elliott, Lloyd T. , Hofer, Edith, Bis, Joshua C. , Jahanshad, Neda , Li, Shuo , Logue, Mark, Scholz, Markus , Smith, Albert V. , Trompet, Stella , Alfaro‐Almagro, Fidel , Ames, David, Amin, Najaf , Beiser, Alexa S., Brodaty, Henry , Fennema‐Notestine, Christine , Gampawar, Piyush , Gottesman, Rebecca, Griffanti, Ludovica , Kral, Brian G. , Lampe, Leonie, Liewald, David C. , Maillard, Pauline , Marchini, Jonathan, Bastin, Mark E., Pirpamer, Lukas , Roshchupkin, Gennady V. , Stott, David J., Thalamuthu, Anbupalam , Tzourio, Christophe , Grond, Jeroen van der , Vernooij, Meike W. , Witte, A. Veronica , Wright, Margaret J. , Yang, Qiong, Siggurdsson, Siggi, Psaty, Bruce M., Villringer, Arno , Schmidt, Helena, Duijn, Cornelia M. van , Jukema, J. Wouter , Dichgans, Martin , Sacco, Ralph L., Kremen, William S., Becker, Lewis C. , Thompson, Paul M., Mosley, Thomas H. , Wardlaw, Joanna M. , Ikram, M. Arfan , Adams, Hieab H.H. , Seshadri, Sudha , Sachdev, Perminder S. , Smith, Stephen M. , Launer, L. J., Longstreth, W.T. , DeCarli, Charles , Schmidt, Reinhold, Fornage, Myriam , Debette, Stéphanie , DeCarli, Charles , Dichgans, Martin , Wardlaw, Joanna Marguerite , Thalamuthu, Anbupalam , Wen, Wei , Adams, Hieab H H , Satizabal, Claudia L , Seshadri, Sudha , Brodaty, Henry , Sachdev, Perminder S , Wright, Margaret J , Tzourio, Christophe , van Duijn, Cornelia M , Debette, Stephanie , Smith, Albert V , Maillard, Pauline , Hofer, Edith , Luciano, Michelle , Vojinović, Dina , Xia, Rui , Amouyel, Philippe , Deary, Ian J. , Jack, Clifford R. , Jenkinson, Mark , Jiang, Jiyang , Kwok, John B. , Marchini, Jonathan , Mazoyer, Bernard , Romero, José R. , Schofield, Peter R. , Schroeter, Matthias L , Trollor, Julian N , Morris, Zoë , Psaty, Bruce M. , Håberg, Asta K , Wright, Clinton B. , Thompson, Paul M. , Nyquist, Paul

Mayo Clinic

Stroke | June 10, 2020 | Volume: 51 | Issue: 7 | Pages: 2111-2121

10.1161/strokeaha.119.027544 | PMID 32517579 Get It

Background and Purpose: Periventricular white matter hyperintensities (WMH; PVWMH) and deep WMH (DWMH) are regional classifications of WMH and reflect proposed differences in cause. In the first study, to date, we undertook genome-wide association analyses of DWMH and PVWMH to show that these phenotypes have different genetic underpinnings. Methods: Participants were aged 45 years and older, free of stroke and dementia. We conducted genome-wide association analyses of PVWMH and DWMH in 26,654 participants from CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology), ENIGMA (Enhancing Neuro-Imaging Genetics Through Meta-Analysis), and the UKB (UK Biobank). Regional correlations were investigated using the genome-wide association analyses -pairwise method. Cross-trait genetic correlations between PVWMH, DWMH, stroke, and dementia were estimated using LDSC. Results: In the discovery and replication analysis, for PVWMH only, we found associations on chromosomes 2 ( NBEAL ), 10q23.1 ( TSPAN14/FAM231A ), and 10q24.33 ( SH3PXD2A). In the much larger combined meta-analysis of all cohorts, we identified ten significant regions for PVWMH: chromosomes 2 (3 regions), 6, 7, 10 (2 regions), 13, 16, and 17q23.1. New loci of interest include 7q36.1 ( NOS3 ) and 16q24.2. In both the discovery/replication and combined analysis, we found genome-wide significant associations for the 17q25.1 locus for both DWMH and PVWMH. Using gene-based association analysis, 19 genes across all regions were identified for PVWMH only, including the new genes: CALCRL (2q32.1), KLHL24 (3q27.1), VCAN (5q27.1), and POLR2F (22q13.1). Thirteen genes in the 17q25.1 locus were significant for both phenotypes. More extensive genetic correlations were observed for PVWMH with small vessel ischemic stroke. There were no associations with dementia for either phenotype. Conclusions: Our study confirms these phenotypes have distinct and also shared genetic architectures. Genetic analyses indicated PVWMH was more associated with ischemic stroke whilst DWMH loci were implicated in vascular, astrocyte, and neuronal function. Our study confirms these phenotypes are distinct neuroimaging classifications and identifies new candidate genes associated with PVWMH only.